SeaStar Medical Q2 net loss widens to $3.7M; cash at $13K; FDA setback on pediatric device

SeaStar Medical Holding Corp

2023-Q2 EPS reported -$0.64

Net loss $3.7M ($0.25/sh) vs $0.9M ($0.12) in Q2 2022; R&D up to $2.0M, G&A $1.7M.
Cash only $13K as of June 30; raised $3.3M convertible debt in March, $2.2M in May, $543K note in August.
FDA HDE application for pediatric SCD-PED not approvable; working with FDA for resubmission.
Two sites activated for adult NEUTRALIZE-AKI trial; expects SCD-ADULT approval H1 2025, launch H2 2025.
Business update call on Aug 22, 2023 at 4pm ET.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SeaStar Medical Holding Corp reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 14, 2023, SeaStar Medical Holding Corporation (the “Company”) issued a press release announcing its financial condition and results of operations for the fiscal quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

SeaStar Medical Holding Corp filing history →

Source: SEC EDGAR

accession 0000950170-23-042572

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.